The project will receive public funding under the France 2030 initiative. Credit: Gorodenkoff via Shutterstock.

Pharmaceutical company Orano Med has commenced construction of its manufacturing facility, Alpha Therapy Laboratory (ATLab) Valenciennes, in Onnaing, France. 

The lab is said to become Europe’s first industrial-scale facility dedicated to the production of lead-212-based radioligand therapies.  

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Once built, the facility will help address the production challenges of these therapies and meet the needs of cancer patients with limited treatment options. 

The ground-breaking ceremony for the facility was attended by Onnaing mayor Xavier Jouanin; Valenciennes Métropole president and Valenciennes mayor Laurent Degallaix; as well as regional councillor for the Circular Economy Aurore Colson, among others.

Targeted Alpha Therapy uses lead-212 to combine biological molecules’ targeting capabilities with the cell-killing properties of alpha emissions.  

See Also:

The facility, spanning more than 3,000m², represents an investment of €29m ($31.24m). 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Orano Projects & Innovation R&D and Nuclear Medicine senior executive vice-president Guillaume Dureau said: “The ATLab in Onnaing is a very important step in our development strategy and is situated at the very heart of the industrial fabric of the Valenciennes metropolitan area and the Hauts-de-France region.  

“The expansion of our production capacity in the radiopharmaceutical field is part of a drive to revitalise our country’s industrial and economic fabric.” 

The development is expected to create 25 direct jobs and will concentrate on producing and distributing lead-212 therapies developed by Orano within Europe.

It has also been selected under the France 2030 plan and will receive public funding of approximately €3.8m to work towards this.